PMID- 34689790
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211028
IS  - 1758-5996 (Print)
IS  - 1758-5996 (Electronic)
IS  - 1758-5996 (Linking)
VI  - 13
IP  - 1
DP  - 2021 Oct 24
TI  - Ten-year follow-up of sitagliptin treatment in patients with type 2 diabetes 
      mellitus.
PG  - 117
LID - 10.1186/s13098-021-00735-3 [doi]
LID - 117
AB  - BACKGROUND: Early and effective intervention with a dipeptidyl peptidase 4 
      inhibitor (DPP4i) before the development of advanced atherosclerosis in type 2 
      diabetes mellitus (T2DM) patients without a history of cardiovascular disease 
      (CVD) is reported to increase the chance of significant reductions in not only 
      microvascular disease, but also CVD. METHOD: This study aimed to investigate 
      whether sitagliptin is effective and tolerated for glycemic control and whether 
      renoprotective effects and beta-cell function are preserved for as long as ten years 
      in Japanese patients with T2DM without a history of CVD. RESULTS: The situation 
      is equivalent to improving glycemic control as assessed by hemoglobin A1c both in 
      a sitagliptin group [sitagliptin 50 mg as either monotherapy or combination 
      therapy with other oral glucose-lowering drugs (n = 17)] or a control group 
      [placebo as either monotherapy or combination therapy with other glucose-lowering 
      drugs (n = 9)], while anti-inflammatory effects as assessed by high-sensitivity 
      C-reactive peptide in the sitagliptin group were superior to those in the control 
      group. In the sitagliptin group, mean urinary albumin excretion (measured as 
      urinary albumin-to-creatinine ratio) was markedly decreased, but no changes in 
      estimated glomerular filtration rate were seen throughout the study. Beta-cell 
      function as evaluated by homeostatic model assessment of beta-cell function values 
      was reduced at baseline in both groups, improved significantly in the sitagliptin 
      group, and continued unchanged in the control group during the study. CONCLUSION: 
      These observations suggest that early intervention with sitagliptin in patients 
      with T2DM may have long-lasting renoprotective and islet-protective effects. 
      TRIAL REGISTRATION: UMIN Clinical Registry (UMIN000038459). Registered 01 
      November (retrospectively registered): https://upload.umin.ac.jp/UMIN000038459.
CI  - (c) 2021. The Author(s).
FAU - Hattori, Sachiko
AU  - Hattori S
AUID- ORCID: 0000-0002-4580-4382
AD  - Department of Endocrinology and Metabolism, Tohto Clinic, 4-1 Kioi-Cho, 
      Chiyoda-Ku, Tokyo, 102-0094, Japan. sh07172017@olive.plala.or.jp.
LA  - eng
PT  - Journal Article
DEP - 20211024
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC8542356
OTO - NOTNLM
OT  - Albuminuria-reducing effect
OT  - Dipeptidyl peptidase 4 inhibitor (DPP4i)
OT  - Islet-protective effect
OT  - Sitagliptin
COIS- There are no conflicts of interest to declare.
EDAT- 2021/10/26 06:00
MHDA- 2021/10/26 06:01
PMCR- 2021/10/24
CRDT- 2021/10/25 05:39
PHST- 2021/08/29 00:00 [received]
PHST- 2021/10/10 00:00 [accepted]
PHST- 2021/10/25 05:39 [entrez]
PHST- 2021/10/26 06:00 [pubmed]
PHST- 2021/10/26 06:01 [medline]
PHST- 2021/10/24 00:00 [pmc-release]
AID - 10.1186/s13098-021-00735-3 [pii]
AID - 735 [pii]
AID - 10.1186/s13098-021-00735-3 [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2021 Oct 24;13(1):117. doi: 10.1186/s13098-021-00735-3.